A lipid based multi-compartmental system: Liposomes-in-double emulsion for oral vaccine delivery

Liau, Jin Jau; Hook, Sarah; Prestidge, Clive A.; Barnes, Timothy J.

doi:10.1016/j.ejpb.2015.09.018

Cited by 36 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These experiments have shown that liposomes can effectively load and release stable protein. They are also able to elicit Th1/Th2 immunity, reflected by the generation of mucosal and systemic antibody responses [21, 141,149,150]. Finally, these systems can also be decorated with targeting molecules ( e.g .…”

Section: Oral Vaccine Strategies: Delivery Systemsmentioning

confidence: 99%

Current state and challenges in developing oral vaccines

Ramirez

Sharpe

Peppas

2017

Advanced Drug Delivery Reviews

313

275

View full text Add to dashboard Cite

While vaccination remains the most cost effective strategy for disease prevention, communicable diseases persist as the second leading cause of death worldwide. There is a need to design safe, novel vaccine delivery methods to protect against unaddressed and emerging diseases. Development of vaccines administered orally is preferable to traditional injection-based formulations for numerous reasons including improved safety and compliance, and easier manufacturing and administration. Additionally, the oral route enables stimulation of humoral and cellular immune responses at both systemic and mucosal sites to establish broader and long-lasting protection. However, oral delivery is challenging, requiring formulations to overcome the harsh gastrointestinal (GI) environment and avoid tolerance induction to achieve effective protection. Here we address the rationale for oral vaccines, including key biological and physicochemical considerations for next-generation oral vaccine design.

show abstract

Section: Oral Vaccine Strategies: Delivery Systemsmentioning

confidence: 99%

Current state and challenges in developing oral vaccines

Ramirez

Sharpe

Peppas

2017

Advanced Drug Delivery Reviews

313

275

View full text Add to dashboard Cite

show abstract

“…However, as discussed above, vaccines based on live-attenuated pathogens can have limitations related to safety in infants, and thus either non-infectious vectors, or non-living or recombinant subunit vaccines are more attractive, albeit, difficult to deliver. Multiple approaches can improve delivery of vaccines orally, such as by delivering them through microbial or plant based carrier systems, or encapsulating them in microparticles [54], nanoparticles [55], or liposomes [56]. Some of these systems are discussed in the later sections.…”

Section: Mucosal Vaccine Delivery - Routes and Barriersmentioning

confidence: 99%

Mucosal vaccine delivery: Current state and a pediatric perspective

Shakya

Chowdhury

Tao

et al. 2016

Journal of Controlled Release

123

115

View full text Add to dashboard Cite

Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and concludes with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.

show abstract

“…Thus, depending on the loaded drug and therapeutic strategy, liposome properties can vary according to the administration routes. In addition to intravenous administration (parenteral administration), liposome surfaces have been coated with PEG in order to prepare more stable particles for being orally administered in gastric ulcer healing treatments (75) and oral vaccines (76). Liposomes have been also administered for lung delivery by developing aerosolized liposomal formulations containing paclitaxel and cyclosporine A with good in vivo results (77).…”

Section: Liposome Preparation Methodsmentioning

confidence: 99%

Liposomes‐in‐Chitosan Hydrogels: Challenges and Opportunities for Biomedical Applications

Grijalvo

Eritja

Díaz

2019

Materials Science and Technology

View full text Add to dashboard Cite

4 drug delivery (17) and tissue engineering (e.g. bone (18), cartilage (18,19) or neural (20) tissue regenerations). From the structural point of view, CS is a linear polysaccharide made of randomly distributed mixtures of deacetylated residues (β-(14)-linked-D-glucosamine) and acetylated residues (N-acetyl-Dglucosamine). This polysaccharide is commercially produced by deacetylation of chitin ( Figure 1A). The percentage of deacetylated and acetylated residues (so-called degree of deacetylation, DA) in CS determines its physicochemical properties as well as solubility (21), biodegradability and biological activity (22).The protonation of the amino groups on the CS backbone under acidic conditions permits the biopolymer solubility before reaching pH values that can range from 6.2 and 6.5. As a consequence, the amino groups of the Dgalactosamine units are predominantly positively charged at pH values below 6.2 (23, 24). The development of physical entanglements in CS hydrogels is governed by reversible non-covalent forces such as hydrogen, ionic and/or hydrophobic intermolecular interactions that depend on the pH, temperature, chemical composition and polymer chain length (24,25,26). Importantly, the robustness of CS-based hydrogels permits the incorporation of small molecules during the gelation process under mild conditions. In this regard, β-glycerophosphate (GP) has been described as an efficient catalyst to trigger the CS sol-to-gel transition at physiological pH. This process has led to transparent physically cross-linked hydrogels with potential use as injectable biomaterials (24) ( Figure 1B). Other small anionic molecules have also been described as effective ionic cross-linking agents including a) citrate and sulphates, b) transition metal ions like Pt (II) (27) or Mo (IV) (28), and c) the use

show abstract

A lipid based multi-compartmental system: Liposomes-in-double emulsion for oral vaccine delivery

Cited by 36 publications

References 42 publications

Current state and challenges in developing oral vaccines

Current state and challenges in developing oral vaccines

Mucosal vaccine delivery: Current state and a pediatric perspective

Liposomes‐in‐Chitosan Hydrogels: Challenges and Opportunities for Biomedical Applications

Contact Info

Product

Resources

About